Brazil’s national sanitary regulator Anvisa today (Dec. 11) is ending its in-loco inspection initiated on Monday (7) at Chinese company Wuxi Biologics, tasked with the manufacture of biological active supplies used by Fiocruz in the production of vaccine AstraZeneca/Oxford.
The inspectors sent to China to check on the practices adopted in the production of supplies await a response from Wuxi Biologics regarding additional data requested, before they can draft a report. Only then is the certification process concluded.
In a note, Anvisa reports that the certificate of good practices in manufacture is ready by the first half of January.
Yesterday (10), Anvisa approved a resolution making it possible “for laboratory to request authorization for the experimental emergency use of vaccines against COVID-19.”
The decision formalizes the request for emergency use announced on December 2 by the watchdog itself.
The post Anvisa ends inspection at AstraZeneca factory first appeared on Portalrondonia.com Notícias locais e do Brasil.
